Type I interferons (IFN-a/-b) are capable of suppressing c-myc mRNA expression by modulating post-transcriptional processing. However, the molecular mechanism of this phenomenon is poorly understood. We previously established that human polynucleotide phosphorylase (hPNPase might be a novel therapeutic strategy for c-myc-overexpressing and IFN-resistant tumors, such as melanomas.
old-35
), a type I IFNinducible 3 0 ,5 0 exoribonuclease involved in mRNA degradation, induces G 1 cell cycle arrest and eventually apoptosis by specifically degrading c-myc mRNA. We now demonstrate a close association between IFN-b-induced hPNPase old-35 upregulation and c-myc downregulation in human melanoma cells. Employing stable melanoma cell clones expressing hPNPase old-35 small inhibitory RNA, we demonstrate that hPNPase old-35 is a key molecule coupled with IFN-b-mediated downregulation of c-myc mRNA. Inhibition of hPNPase old-35 or overexpression of c-myc protects melanoma cells from IFN-bmediated growth inhibition, emphasizing the importance of hPNPase old-35 upregulation and consequent c-myc downregulation in IFN-b-induced growth inhibition and apoptosis induction. In these contexts, targeted overexpression of hPNPase
Introduction
Interferons (IFNs) comprise a family of secreted cytokines displaying divergent activities, including protection against viral and bacterial infections, antitumor activity (both direct and immune system mediated) and stimulating or inhibiting differentiation depending on cellular context. 1, 2 Five classes of IFNs are currently recognized, including IFN-a, IFN-b, IFN-g, IFN-t (bovine) and IFN-o, which display distinct biological activities, mode of induction and amino-acid sequence. 1, 2 Type I and II IFNs are classified based on interactions with their respective type I or II cell surface receptors. IFN-a (12 subtypes), IFN-b, IFN-t and IFN-o interact with type I IFN receptors and IFN-g binds and signals through type II IFN receptors. 1, 2 Although crosstalk between additional receptors and signaling pathways has been documented, biochemical approaches and genetic complementation studies using mutant cells demonstrate that the predominant signaling pathway that mediates activation of IFN-responsive genes involves JAK tyrosine kinases and signal transducers and activators of transcription (STATs).
1,2 Binding of IFN-g with its cognate receptors results in phosphorylation (activation) of JAK1 and JAK2, which phosphorylates STAT1 that homodimerizes, translocates to the nucleus and binds to gammaactivated sequence (GAS) elements in the promoters of target genes to augment transcription. 1, 2 Type I IFN binding to cognate receptors results in sequential phosphorylation of Tyk2, JAK1, STAT1 and STAT2, and STAT1/STAT2 heterodimer translocates into the nucleus and interacts with IRF family transcription factor p48, thus generating the ISGF3 transcription factor complex that binds to interferon-stimulated regulatory elements (ISRE) in target promoters to drive transcription. 1, 2 Although the transcriptional regulation of IFNstimulated genes (ISGs) is well-understood, IFNs also downregulate the expression of many genes (http://bioinfo.cnio.es/ data/oncochip/) and the mechanism underlying this process is still unclear.
Human polynucleotide phosphorylase (hPNPase old-35 ) is a type I IFN-inducible early response gene. [3] [4] [5] [6] Biochemically, hPNPase old-35 is a 3 0 ,5 0 exoribonuclease catalyzing mRNA decay in a 3 0 -5 0 direction. 3 Polynucleotide phosphorylase (PNPase) is an evolutionary conserved gene and the bacterial and plant enzymes have been cloned and extensively studied for decades. 5 The human homolog was recently identified by our laboratory using a unique cloning strategy termed 'overlapping pathway screening' (OPS), in which a terminally differentiated human melanoma cDNA library was screened with cDNAs derived from senescent fibroblasts. 3 Terminal differentiation of human melanoma cells, induced by combined treatment with IFN-b and the protein kinase C activator mezerein (MEZ), and cellular senescence share several common end points, one of which is irreversible growth arrest, and the premise underlying the OPS approach was to identify genes that are critical mediators of two significant physiological processes, namely terminal differentiation and senescence. 7, 8 In total, 75 ESTs, termed old 1-75, were identified by OPS and old-35, which was later recognized to be the human version of PNPase, was found to be consistently overexpressed during the terminal differentiation process in human melanoma cells and senescent human fibroblasts. 3 While its expression was virtually undetectable in human melanoma cells under basal condition, hPNPase old-35 was markedly induced within 6 h following treatment with IFN-b, highlighting a potentially prominent role in mediating IFN-b-induced molecular events. 3 Of direct relevance to the present study, overexpression of hPNPase old-35 via an adenoviral vector (Ad.hPNPase old-35 ) induces profound morphological, biochemical and gene expression changes that mimic the critical molecular and biochemical signatures of senescence as well as differentiation. 6 hPNPase old-35 induces cell cycle arrest in the G 1 phase with inhibition of DNA synthesis and telomerase activity, and activates the senescence-associated b-galactosidase enzyme. 6 Moreover, hPNPase old-35 induces gene expression changes that are consistent with G 1 cell cycle arrest, such as downregulation of c-myc, upregulation of p27 KIP-1 and hypophosphorylation of Rb. 6 We previously found that downregulation of c-myc plays a critical part in hPNPase old-35 -induced growth inhibition, since overexpression of c-myc partially but significantly ablated this growth-inhibitory effect. 6, 9 In vitro mRNA degradation assays revealed that, as an exoribonuclease, hPNPase old-35 directly and specifically degraded c-myc mRNA.
6 hPNPase old-35 contains an Nterminal mitochondrial localization signal and its predominant site of localization is in the mitochondria.
9,10 However, we have recently documented that in addition to mitochondrial localization a considerable amount of hPNPase old-35 also resides in the cytoplasm, thus explaining the conundrum of how a mitochondrial exoribonuclease could degrade a cytoplasmic mRNA, like c-myc. 10 The molecular mechanism of regulation of c-myc expression by IFN-b still represents an enigma. It has been two decades since it was first demonstrated that IFN-b downregulated c-myc expression and this downregulation involved modulation of post-transcriptional control of c-myc mRNA. 11, 12 However, the molecules and biochemical pathways involved in this post-transcriptional control remain to be elucidated. We previously demonstrated that hPNPase old-35 was induced very early upon IFN-b treatment and hPNPase old-35 could specifically degrade c-myc mRNA. 3, 6, 9 Based on these observations, we reasoned that hPNPase old-35 might be a key molecule regulating IFN-b-mediated downregulation of c-myc mRNA. Employing stable cell clones expressing hPNPase old-35 small inhibitory RNA (siRNA) and c-myc, we now provide experimental validation of this hypothesis and establish for the first time the importance of upregulation of is also required to downregulate Myc protein, indicating a potential cooperative regulation in the expression of these two genes.
The regulation of expression of hPNPase old- 35 and Myc by IFN-b was confirmed in 2fTGH human fibrosarcoma cells and in its four variants, U1A (Tyk2-), U3A (STAT1-), U4A (JAK1-) and U5A (IFNAR2-), which have mutations in different molecules involved in the IFN-signaling pathway. 13 As shown in Figure 1C , the upregulation of hPNPase old-35 and downregulation of Myc by IFN-b were observed only in parental 2fTGH cells but not in its mutant clones, which are nonresponsive to type I IFN. The results obtained using cell viability assays were confirmed by colony formation assays (Figure 2b ). In HO-1, WM-35 and FM-516 cells colony formation was significantly inhibited with 100 U/ml of IFN-b and, with 1000 U/ml, the colony formation was inhibited by 490%. In the case of MeWo cells, 10 U/ml of IFN-b significantly inhibited colony formation and with 1000 U/ml of IFN-b colony formation was inhibited by 495%.
IFN-b inhibits growth of melanoma cells and melanocytes
Cell cycle analysis was performed to characterize growth inhibition. IFN-b treatment (1000 U/ml) in HO-1, WM-35, MeWo and FM-516 cells resulted in initial (day 1) cell cycle arrest in the G 1 phase of the cell cycle, with a concomitant Figure 3A (1000 U/ml) for 24 h and then exposed to Act-D (5 mg/ml) for 0.5, 1, 2, 4 and 8 h, after which the cells were harvested for total RNA extraction and Northern blot analysis using the indicated probes -siRNAexpressing clones to IFN-b-induced inhibition of colony formation ( Figure 5) .
The results obtained from cell survival and colony formation assays were confirmed by cell cycle analysis using flow cytometry. As shown in Figure 6 and Table 2 , the parental HO-1 cells and control siRNA-expressing clones showed an initial G 1 arrest and eventually cells underwent apoptosis. However, hPNPase old-35 -siRNA-expressing clones showed remarkable resistance to growth inhibition by IFN-b, with no statistically significant increase in the G 1 phase or the number of A 0 cells. In these contexts, blocking hPNPase old-35 expression prevents cell cycle arrest and apoptosis induced by IFN-b.
To confirm that the mechanism underlying the resistance of hPNPase old-35 -siRNA-expressing clones to IFN-b is mediated by their inability to downregulate c-myc, HO-1 cells and control siRNA-and hPNPase old-35 -siRNA-expressing clones were transfected with either control or c-myc siRNA and These interesting findings were corroborated by cell cycle analysis. Treatment with IFN-b induced an initial G 1 arrest and eventually apoptosis in HO-1-Hygro clones ( Table 3 ). The HO-1-Myc clones showed a slight increase in the percentage of G 1 phase and apoptotic cells following IFN-b treatment, which was not statistically significant. These findings indicate that both upregulation of hPNPase old-35 and downregulation 
Discussion
Microarray studies have revealed a plethora of genes that are modulated by IFN treatment 14 (http://bioinfo.cnio.es/data/ oncochip/). IFNs can directly affect gene expression by ISRE and GAS sequences in the promoters of target genes. 1 In addition, IFNs can also affect gene expression by their ability to induce proteins involved in RNA metabolism, such as 2 0 , 5 0 -oligoadenylate synthetase/RNase L, double-stranded RNA-dependent protein kinase (PKR), melanoma differentiation-associated gene-5 (mda-5), retinoic acid-inducible gene-I (RIG-I) and hPNPase old-35 . Inhibition of gene expression by IFNs at a post-transcriptional level has been described for the heavy chain of immunoglobulin mu, 15 the IL-4 receptor 16 and c-myc, 11 ,12 the focus of the present studies. The observation that type I IFN selectively reduces c-myc mRNA has been described in multiple studies using several model cell culture systems. Jonak and Knight first hypothesized that IFN-b mediated downregulation of c-myc mRNA might mediate growth inhibition in Daudi human lymphoblastoid cells. 11 As a follow-up study, Dani et al. demonstrated in Daudi cells that IFN a/b did not affect the transcription rate of c-myc mRNA, but rather reduced the half-life of this mRNA. 12 A post-transcriptional destabilization of c-myc mRNA as a mechanism of type I IFN-mediated c-myc suppression has also been described in colon carcinoma cells. 17 It was shown that, during terminal differentiation of hematopoietic cells, autocrine IFN-b induces c-myc suppression and induces G 0 /G 1 arrest in these cells. 18 Additionally, previous studies from our laboratory documented that IFN-b and MEZ-induced terminal differentiation of human melanoma cells also correlated with downregulation of c-myc mRNA. 19 Moreover, studies in different cell types consistently describe the ability of type I IFN to reduce c-myc expression. However, the effect of IFN-g on c-myc expression varies in different cell contexts. In HeLa cells, treatment with IFN-a decreased, while IFN-g increased c-myc expression. 20 In a murine myeloid cell line, IFN-g inhibited c-myc gene expression by impairing the splicing process. 21 Another report described the importance of Stat-1 in IFN-g-mediated downregulation of c-myc. Studies employing wild type and Stat-1-null mouse embryonic fibroblasts identified a GAS element in the c-myc promoter that was necessary, but not sufficient, to suppress c-myc expression in wild-type cells. 22 Although a consensus exists that type I IFNs induce posttranscriptional modulation of c-myc mRNA, the molecular mechanism underlying this process is unclear. Different components of IFN-inducible RNA degradation machinery have been implicated in this action. In colon carcinoma cells, 2 0 ,5 0 -oligoadenylate synthetase/RNase L system is believed to regulate IFN-b-mediated post-transcriptional processing of c-myc mRNA. 17 In M1 murine myeloid leukemia cells, PKR has been shown to mediate type I IFN-induced c-myc suppression. 23 A recent report indicates that in mouse 24 In our previous studies, we revealed for the first time by employing recombinant hPNPase old-35 protein in in vitro mRNA degradation assays that a type I IFNinducible exoribonuclease, hPNPase old-35 , could selectively degrade c-myc mRNA. 6, 9 In the present studies, we now confirm that hPNPase old-35 is the enzyme responsible for IFNb-mediated degradation of c-myc mRNA in human melanoma cells.
Myc is an important regulator of cell proliferation. 25 Expression of exogenous Myc in cultured fibroblasts promotes S-phase entry and shortens the G 1 phase of the cell cycle, while activation of a conditional Myc is sufficient to drive quiescent cells into the cell cycle. An association between cmyc downregulation and IFN-a-mediated G 0 /G 1 arrest in Daudi cells was demonstrated, 26 and it was shown that IFN-ainduced G 0 /G 1 arrest correlated with upregulation of cyclindependent kinase inhibitors (CDKI), such as p21 and p15 early in this process and p27 in the late stage of growth arrest. 27 Type I IFN treatment of Daudi cells induced p21 expression and G 1 arrest, and these events were preceded by a strong reduction in c-myc levels. 28 Myc can directly suppress the transcription of p21 and p27 and promote the ubiquitination of phosphorylated p27. 25 Our previous experiments confirm that overexpression of hPNPase old-35 downregulates c-myc and upregulates p27, 6 and in the present study we document that inhibition of hPNPase old-35 as What is the practical significance of our observations? Myc is overexpressed in multiple tumor subtypes, including melanomas. 25 The expression level of Myc inversely correlates with patient survival and thus may be used as a prognostic marker in different melanomas. [29] [30] [31] [32] Indeed, antisense inhibition of c-myc significantly inhibited the growth of melanoma cells in in vitro cultures 33 and improved the response to chemotherapy in human melanoma xenografts in nude mice. 34 Type I IFNs have been used as adjuvant therapy for malignant melanoma with significant but limited success and high toxicity. 35 Experimental overexpression of Myc in mouse fibroblasts and myeloblastic cells renders these cells resistant to cell cycle arrest by type I IFNs. 36, 37 Uveal melanomas with high c-myc expression are also associated with IFN-a resistance. 38 In these contexts and based on the poor survival of patients with malignant melanoma, improved therapies are mandated and cancer-cell-specific expression of hPNPase old-35 , by means of the telomerase or progression elevated gene-3 promoter, 39, 40 might prove beneficial as an innovative adjuvant therapeutic approach that exploits the ability of hPNPase old-35 to degrade c-myc mRNA, thus inducing target cancer cell-specific growth arrest culminating in apoptosis.
Materials and Methods
Cell lines and cell viability assays FM516-SV (referred to as FM516) normal immortal human melanocyte, WM35 early radial growth phase (RGP) primary human melanomas, HO-1 and MeWo metastatic melanomas, 2fTGH human fibrosarcoma and its derivates U1A, U3A, U4A and U5A, HeLa human cervical carcinoma and 293 adenovirus transformed human embryonic kidney (HEK 293) cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and penicillin (100 U/ml) and streptomycin (100 mg/ml). 2fTGH cells are wild type in IFN signaling, while its derivates U1A, U3A, U4A and U5A have defects in IFN signaling that could be complemented by expression of TYK2, STAT1, JAK1 or IFNAR2, respectively. 13 Cell growth and viable cell numbers were monitored by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) staining as described. 6 Generation of lentivirus expressing siRNA for hPNPase old-35 Using the software siRNA Target Finder (Ambion, Austin, TX, USA), four potential siRNAs for hPNPase old-35 were designed and the siRNAs were constructed by in vitro transcription using the Silencer siRNA construction kit (Ambion) according to the manufacturer's protocol. These siRNAs were transfected into HeLa cells using 
Generation of stable cell clones
Stable clones of HO-1 cells expressing either control siRNA or hPNPase old-35 siRNA were generated by transducing the cells with lentiviruses expressing the corresponding siRNA and selecting clones for 2 weeks using 4 mg/ml blasticidin. Stable HO-1 clones expressing c-myc were generated by transfecting HO-1 cells with a c-myc expression vector and selecting the cells for 2 weeks with 100 mg/ml hygromycin. Transfecting the cells with empty vector and selecting with hygromycin generated the corresponding control clones.
Cell cycle analysis
Cells were harvested, washed in PBS and fixed overnight at À201C in 70% ethanol. The cells were treated with RNase A (1 mg/ml) at 371C for 30 min and then with propidium iodide (50 mg/ml). Cell cycle was analyzed using a FACScan flow cytometer and data were analyzed using CellQuest software (Becton Dickinson, San Jose, CA, USA).
Colony formation assays
In total, 1000 cells were plated in 6-cm dishes and then treated with different doses of IFN-b for 2 weeks, at which point the colonies were fixed, stained with Giemsa and colonies X50 cells were counted. 5 were plated in a 6 cm dish and the next day were transfected with 25 nM of either control siRNA or c-myc siRNA (Ambion; catalogue# 4250) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. After 24 h, the cells were trypsinized and seeded into 96-well plates for cell viability assays and 6-cm dishes for colony formation assays and cell cycle analyses as described above.
RNA isolation and Northern blot analysis
Total RNA was extracted from cells using Qiagen RNeasy mini kit (Qiagen) according to the manufacturer's protocol and Northern blotting was performed as described. 6 The cDNA probes used were a 400-bp fragment from human c-myc, a 500-bp fragment from hPNPase old-35 and full-length human GAPDH. For analysis of the half-life of c-myc mRNA, cells were either untreated or treated with IFN-b (1000 U/ml) for 24 h and then treated with Act-D (5 mg/ml) for 0.5, 1, 2, 4 and 8 h, following which the cells were harvested for total RNA extraction and Northern blot analysis.
Western blot analysis
Western blotting was performed as described previously. 6 Briefly, cells were harvested in RIPA buffer containing protease inhibitor cocktail (Roche, Mannheim, Germany), 1 mM Na 3 VO 4 and 50 mM NaF and centrifuged at 12 000 r.p.m. for 10 min at 41C. The supernatant was used as total cell lysate. In all, 30 mg of total cell lysate was used for SDS-PAGE and transferred to a nitrocellulose membrane. The primary antibodies included: Myc (1 : 200; mouse monoclonal; Santa Cruz biotechnology, Santa Cruz, CA, USA), hPNPase old-35 (1 : 10000; chicken polyclonal), MDA-5 (1 : 5000; rabbit polyclonal) and EF1a (1 : 1000; mouse monoclonal; Upstate Biotechnology, Waltham, MA, USA).
Statistical analysis
Statistical analysis was performed using one-way analysis of variance (ANOVA), followed by Fisher's protected least significant difference analysis.
